Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Villani, P. Articles by Bergomi, R. Search for Related Content PubMed PubMed Citation Articles by Villani, P. Articles by Bergomi, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 936-937, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.936-937.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Cerebrospinal Fluid Linezolid Concentrations in Postneurosurgical Central Nervous System Infections

Top Letter References

 
Gram-positive (GP) cocci, mainly methicillin-resistant staphylococci, are the most frequent pathogens involved in central nervous system (CNS) postneurosurgical infections (4). Linezolid (PNU-100766), a synthetic oxazolidinone, has shown good in vitro and in vivo activities against drug-susceptible and drug-resistant staphylococci, streptococci, and enterococci, with MICs for 90% of the isolates generally ranging from 0.5 to 4 µg/ml (6). Linezolid has shown good CNS penetration and thus seems a promising candidate for treatment of CNS infections (1, 2); however, at present, only a few anedoctal data, dealing with vancomycin-resistant-enterococcus meningitis, have been reported about efficacy and safety in this setting (3, 7, 8).

As part of an expanded-access program for patients with nosocomial infections, we assayed the plasma and cerebrospinal fluid (CSF) linezolid levels in five patients treated for postneurosurgical CNS infections due to GP pathogens and with a history of either failure to respond to or untoward events with vancomycin-based regimens (Table 1). Linezolid was administered intravenously (1-h infusion) at the dosage of 600 mg twice a day (mean treatment time, 20 days). Patients received no other antimicrobials. Plasma and CSF specimens were collected simultaneously after multiple doses and assayed for linezolid concentrations by a specific high-performance liquid chromatography technique (5). Clinical features and outcome will be detailed elsewhere. Briefly, during linezolid treatment, clinical signs improved dramatically, with both complete clinical resolution and normalization of CSF findings in all patients.

View this table: [in this window] [in a new window]

TABLE 1. Concentrations of linezolid in plasma and CSF and other clinical data for five patients with CNS infections

Plasma linezolid trough concentrations ranged from 0.54 to 5.3 µg/ml, CSF linezolid trough levels ranged from 1.46 to 7.0µg/ml, and the ratio between CSF and plasma linezolid trough concentrations always exceeded 1 (mean, 1.6; range, 1.2 to 2.3) (Table 1). Importantly, CSF linezolid trough concentrations largely exceeded the MICs for the four isolates in our patients. Also, these findings were recorded after at least 6 days of treatment, when the blood-brain barrier permeability could have had a trend towards normalization.

These findings parallel those of Shaikh et al. (7), who observed CSF/plasma ratios of trough drug concentrations of 17 (2.39/0.14 µg/ml) and 1.9 (2.98/1.53 µg/ml) after 2 and 19 days, respectively, in one patient affected with vancomycin-resistant-enterococcus meningitis, successfully treated with 600 mg of intravenous linezolid.

Also, the relatively constant CSF linezolid concentration observed at the end of 1-h drug infusion confirms a slow flow of linezolid across the blood-brain barrier, as suggested by Shaikh (7).

As a matter of fact, CSF linezolid peak concentrations are relatively delayed, and the CSF/plasma trough ratios obtained in our study and in Shaikh et al.'s are higher than those in patients without meningitis (6). Such findings, which are in agreement with linezolid's amphiphilic properties (log partition coefficient between n-octanol and water, 0.55), indicate that the severity of meningeal inflammation could influence penetration of linezolid into the brain and the CSF.

Even though a complete pharmacokinetic profile of linezolid in CSF could not be obtained, our results show that the daily dose of 600 mg produces plasma and CFS linezolid concentrations greater than those predicted to be effective against a variety of clinically important multidrug-resistant cocci (6).

Top Letter References

 

1
1. Cottagnoud, P., C. M. Gerber, F. Acosta, M. Cottagnoud, K. Neftel, and M. G. Tauber. 2000. Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J. Antimicrob. Chemother. 46:981-985.[Abstract/Free Full Text]
2
2. Gemmell, C. G. 2001. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J. Antimicrob. Chemother. 48:47-52.[Abstract/Free Full Text]
3
3. Hachem, R., C. Afif, Z. Gokaslan, and I Raad. 2001. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur. J. Clin. Microbiol. Infect. Dis. 20:432-434.[CrossRef][Medline]
4
4. Ostabal, M. I., M. A. Suarez Pinilla, C. Sanz Sebastian, and A. Millastre. 1996. Epidemiological study of nosocomial meningitis in neurological patients. Rev. Neurol. 24:265-267.[Medline]
5
5. Peng, G. W., R. P. Stryd, S. Murata, M. Igarashi, K. Chiba, H. Aoyama, M. Aoyama, T. Zenki, and N. Ozawa. 1999. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J. Pharm. Biomed. Anal. 20:65-73.[CrossRef][Medline]
6
6. Perry, C. M., and B. Jarvis. 2001. Linezolid. A review of its use in the management of serious gram-positive infections. Drugs 61:525-551.[CrossRef][Medline]
7
7. Shaikh, Z. H. A., C. A. Peloquin, and C. D. Ericsson. 2001. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand. J. Infect. Dis. 33:375-379.[CrossRef][Medline]
8
8. Zeana, C., C. J. Kubin, P. Della-Latta, and S. M. Hammer. 2001. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin. Infect. Dis. 33:477-482.[CrossRef][Medline]

						P. Villani M. B. Regazzi* F. Marubbi Laboratory of Clinical Pharmacokinetics Policlinico San Matteo P. le Golgi 2 27100 Pavia, Italy P. Viale University of Udine Udine, Italy L. Pagani Hospital of Bolzano Bolzano, Italy F. Cristini B. Cadeo G. Carosi University of Brescia Brescia, Italy R. Bergomi Spedali Civili Brescia, Italy
						* Phone: 39 0 382 503471 Fax: 39 0 382 422701 E-mail: regazzim{at}smatteo.pv.it

---

Antimicrobial Agents and Chemotherapy, March 2002, p. 936-937, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.936-937.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Webster, D. P., Griffiths, S., Bowler, I. C. J. W. (2009). Failure of linezolid therapy for post-neurosurgical meningitis due to Enterococcus faecium. J Antimicrob Chemother 63: 622-623 [Full Text]  
• Dinleyici, E. C., Yarar, C., Dinleyici, M., Yakut, A. (2007). Successful Treatment with Linezolid of Meningitis Complicated with Subdural Empyema in a 6-Month-Old Boy. J Trop Pediatr 53: 431-433 [Abstract] [Full Text]  
• Jodlowski, T. Z, Melnychuk, I., Conry, J. (2007). Linezolid for the Treatment of Nocardia spp. Infections. The Annals of Pharmacotherapy 41: 1694-1699 [Abstract] [Full Text]  
• Nagel, S., Kohrmann, M., Huttner, H. B., Storch-Hagenlocher, B., Schwab, S. (2007). Linezolid-Induced Posterior Reversible Leukoencephalopathy Syndrome. Arch Neurol 64: 746-748 [Abstract] [Full Text]  
• Beer, R., Engelhardt, K. W., Pfausler, B., Broessner, G., Helbok, R., Lackner, P., Brenneis, C., Kaehler, S. T., Georgopoulos, A., Schmutzhard, E. (2007). Pharmacokinetics of Intravenous Linezolid in Cerebrospinal Fluid and Plasma in Neurointensive Care Patients with Staphylococcal Ventriculitis Associated with External Ventricular Drains. Antimicrob. Agents Chemother. 51: 379-382 [Abstract] [Full Text]  
• Myrianthefs, P., Markantonis, S. L., Vlachos, K., Anagnostaki, M., Boutzouka, E., Panidis, D., Baltopoulos, G. (2006). Serum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical Patients. Antimicrob. Agents Chemother. 50: 3971-3976 [Abstract] [Full Text]  
• Boak, L. M, Li, J., Spelman, D., Cros, P. d., Nation, R. L, Rayner, C. R (2006). Successful Treatment and Cerebrospinal Fluid Penetration of Oral Linezolid in a Patient with Coagulase-Negative Staphylococcus Ventriculitis. The Annals of Pharmacotherapy 40: 1451-1455 [Abstract] [Full Text]  
• Schriever, C., Zeitz-Colaizzi, L., Quinn, A., Schriever, A. E., Cannon, J. P. (2005). Considerations for the Management of Gram-Positive Pathogens in the Intensive Care Unit. Journal of Pharmacy Practice 18: 100-108 [Abstract]  
• Krueger, W. A., Kottler, B., Will, B. E., Heininger, A., Guggenberger, H., Unertl, K. E. (2004). Treatment of Meningitis Due to Methicillin-Resistant Staphylococcus epidermidis with Linezolid. J. Clin. Microbiol. 42: 929-932 [Abstract] [Full Text]  

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Villani, P. Articles by Bergomi, R. Search for Related Content PubMed PubMed Citation Articles by Villani, P. Articles by Bergomi, R.